Focusing on early and
accurate disease detection.
Leveraging artificial
intelligence for enhanced diagnostic accuracy.
Pioneering
non-invasive methods for comfortable and accessible diagnostics.
Pioneering the next
generation of healthcare diagnostics.
Looking for affordable, rapid
screening tools.
Seeking practical diagnostic solutions for
dogs and cats.
With ideas ready to be
transformed into products.
Seeking to establish their footprint in India fast-growing diagnostics market.
Our R&D pipeline follows a robust, stepwise approach to ensure both scientific credibility and practical usability.
• Concept and Biomarker Selection: Identifying and validating the most reliable biomarkers.
• Prototype Development: Designing and testing lateral flow assays and ELISA kits.
• Validation: Conducting rigorous sensitivity and specificity testing in both human and veterinary samples.
• Clinical Trials: Partnering with hospitals, primary health centers, and veterinary clinics for real-world validation.
• Regulatory Compliance: Ensuring adherence to CDSCO and ISO 13485 standards.
• Commercialization: Preparing for pilot-scale manufacturing, packaging, distribution, and post-market monitoring.
By combining artificial intelligence with biomarker science, BridgeInDx creates diagnostic solutions that are accurate, scalable, and accessible for all.
We believe diagnostics must not only be effective but also visible and trusted. Our branding strategy focuses on:
âÃÂâ Healthcare and Veterinary Expos: Showcasing new diagnostic innovations to the medical and veterinary communities.
âÃÂâ Academic and Clinical Collaborations: Building credibility through partnerships and research publications.
âÃÂâ Digital Campaigns: Promoting accessibility, affordability, and scientific innovation through engaging online content.
âÃÂâ Community Outreach: Bringing awareness programs and diagnostic camps to rural populations and pet owners in regional languages.
BridgeInDx is building a reputation as a brand that represents trust, accessibility, and innovation.
Indias diagnostics market is expanding at an unprecedented pace, projected to grow from 10 billion in 2022 to nearly 1,500 billion by 2028. Within this growth, point-of-care (POC) testing has emerged as one of the fastest-growing categories, with an estimated 18 to 20% CAGR, particularly in rural and semi-urban areas where access to centralized diagnostic laboratories is limited.
Cancer diagnostics represent one of the most urgent and high-potential areas of growth:Lung Cancer:
Lung cancer accounts for 5.9% of all cancersand8.1% of cancer-related deaths in India, with smoking linked to nearly 80% of cases. Over 70% of patients are diagnosed at advanced stages, when treatment is less effective. The Indian market opportunity exceeds $100 million, yet there are currently no POC solutions. Rapid, AI-driven tests for triage and monitoring represent a clear first-mover advantage.
Ovarian Cancer:
Ovarian cancer is the third most common gynecologic cancer in India, with nearly 60,000 new cases reported annually and high mortality due to late detection. Five-year survival rates drop drastically from 90% at early stages to below 30% in advanced stages. With no widely available POC solutions, the market represents an innovation gap estimated to grow at 10 to 12% CAGR, driven by rising awareness in womens health and expanding oncology services.
Colorectal Cancer:
Colorectal cancer is one of the fastest-growing cancers in India, particularly in urban and semi-urban regions. Incidence has increased by over 20% in the last decade, with lifestyle changes contributing to its rise. Current screening options (such as colonoscopy) are invasive, costly, and inaccessible to most of the population. Affordable, stool- and blood-based POC diagnostics integrated with AI could unlock a market with 9 to 11% CAGR growth potential in the coming years.
Bladder Health:
Bladder health issues, including urinary tract infections (UTIs)and bladder cancer, remain largely underdiagnosed in India. The bladder cancer burden alone accounts for ~20,000 new cases annually, with a high rate of missed early detection. The bladder diagnostics market is currently valued at $60 to 80 million, growing at10 to 12% CAGR, but affordable, accurate, non-invasive POC tests are still scarce.
Companion Animal Diagnostics:
With over 30 million pet dogs and 3 million pet cats in India and a pet care industry growing at 12 to 15% CAGR, companion animal diagnostics is an emerging but underdeveloped segment. AI-powered rapid tests for canine and feline health represent a frontier with strong growth potential, fueled by rising disposable income and awareness among pet owners.
BridgeInDx is uniquely positioned at the intersection of these opportunities. With a focus on AI, non-invasive testing, and affordability, we bring first-mover advantage to areas where innovation is urgently needed.
Lung cancer accounts for 5.9% of all cancersand 8.1% of cancer-related deaths in India, with smoking linked to nearly 80% of cases. Over 70% of patients are diagnosed at advanced stages, when treatment is less effective. The Indian market opportunity exceeds $100 million, yet there are currently no POC solutions. Rapid, AI-driven tests for triage and monitoring represent a clear first-mover advantage.
Ovarian cancer is the third most common gynecologic cancer in India, with nearly 60,000 new cases reported annually and high mortality due to late detection. Five-year survival rates drop drastically from 90% at early stages to below 30% in advanced stages. With no widely available POC solutions, the market represents an innovation gap estimated to grow at 10 to 12% CAGR, driven by rising awareness in women health and expanding oncology services.
Colorectal cancer is one of the fastest-growing cancers in India, particularly in urban and semi-urban regions. Incidence has increased by over 20% in the last decade, with lifestyle changes contributing to its rise. Current screening options (such as colonoscopy) are invasive, costly, and inaccessible to most of the population. Affordable, blood-based POC diagnostics integrated with AI could unlock a market with 9 to 11% CAGR growth potential in the coming years.
Bladder health issues, including urinary tract infections (UTIs)and bladder cancer, remain largely underdiagnosed in India. The bladder cancer burden alone accounts for ~20,000 new cases annually, with a high rate of missed early detection. The bladder diagnostics market is currently valued at $60 to 80 million, growing at10 to 12% CAGR, but affordable, accurate, non-invasive POC tests are still scarce.
With over 30 million pet dogs and 3 million pet cats in India and a pet care industry growing at 12 to 15% CAGR, companion animal diagnostics is an emerging but underdeveloped segment. AI-powered rapid tests for canine and feline health represent a frontier with strong growth potential, fueled by rising disposable income and awareness among pet owners.
Identifying and validating the most reliable biomarkers.
Designing and testing lateral flow assays and ELISA kits.
Conducting rigorous sensitivity and specificity testing in both human and veterinary samples.
Partnering with hospitals, primary health centers, and veterinary clinics for real-world validation.
Ensuring adherence to CDSCO and ISO 13485 standards.
Preparing for pilot-scale manufacturing, packaging, distribution, and post-market monitoring. By combining artificial intelligence with biomarker science, BridgeInDx creates diagnostic solutions that are accurate, scalable, and accessible for all.
Showcasing new diagnostic innovations to the medical and veterinary communities.
Building credibility through partnerships and research publications.
Promoting accessibility, affordability, and scientific innovation through engaging online content.
Bringing awareness programs and diagnostic camps to rural populations and pet owners in regional languages. BridgeInDx is building a reputation as a brand that represents trust, accessibility, and innovation.